Untapped Potential in Fc Antibody Engineering
As of 2011, monoclonal antibody therapeutics had become approximately a $45 billion market for the treatment of a host of diseases ranging from cancer to infectious disease. Antibody drug development has traditionally been focused on a component of the antibody known as the variable (Fv) domain which is responsible for targeting and binding to a specific antigen. Very little attention has been given to the constant (Fc) domain, a second essential structural and functional component of the antibody.
Xencor has built a world leading IP position in the Fc domain that has become the foundation of its proprietary antibody engineering platform for optimizing monoclonal antibody therapeutics. Through the application of our XmAb® antibody engineering technology, we have created over 2,000 Fc variants and been granted over 70 patents worldwide and have more than 100 patents pending.